China Biotech Deal Volume Surged 81% as Western Pharma Doubles Down
A BIO China panel based on anonymous survey data from BD heads and senior dealmakers revealed that nearly 80%...
Moe Alsumidaie
Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...
The Vein That Learns to Belong: VERIGRAFT’s Biological Bet on Curing Chronic Venous Insufficiency
Petter Björquist CEO, VERIGRAFT Chronic venous insufficiency affects an estimated 150 million people worldwide, yet the clinical toolkit has...
The Six-Month Shot That Broke HIV’s Business Model: Lenacapavir Is Rewriting Who Wins in a Market Everyone Thought Was Settled
Gilead's lenacapavir approval for HIV PrEP—100% efficacy, twice-yearly dosing—threatens daily-pill incumbents and signals a mechanism arms race across the...
The Drug That Nearly Disappeared: How Convexia Bio Is Using AI Agents to Rescue the Assets Big Pharma Left Behind
A Vanguard Publications Q&A with Ayaan, Convexia Bio.
Novartis Didn’t Build Seven Facilities to Make Drugs — It Built Them to Win a Tariff War
Novartis completes its $23B, seven-facility US manufacturing plan one year after launch — and the API strategy in North...
Regeneron Priced Otarmeni at Zero — And That’s the Most Expensive Move in Ultra-Rare Disease This Decade
Regeneron's FDA-approved gene therapy Otarmeni targets just 20–50 U.S. births yearly. Its free pricing strategy could cost every rare...
Late-Stage or Nothing: How Big Pharma Is Rewriting the M&A Playbook One NDA Away From Filing
Teva's $900M Emalex deal for NDA-ready ecopipam in Tourette syndrome signals a pharma M&A shift: buy at Phase 3...
Coultreon’s $125M Bet Proves the Real Alpha in Biotech Is Knowing Which Shipwrecks Are Worth Salvaging
Coultreon Biopharma raised $125M Series A for rescued Galapagos oncology assets — and the investor syndicate tells you exactly...
China’s Drug Machine Is Handing Western Pharma a Strategic Crisis Disguised as a Partnership Opportunity
China now drives first-in-class innovation, not just generics—and every Western pharma BD team underpricing that shift is building a...